Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Deckers Outdoor (DECK) PT Raised to $100 at Canaccord Genuity; Reiterates Buy
-
VF Corp. (VFC) PT Raised to $90 at Canaccord Genuity
-
Abaxis Inc. (ABAX) PT Raised to $65 at Canaccord Genuity
-
IDEXX Laboratories (IDXX) PT Raised to $210 at Canaccord Genuity, Street High
-
Intuitive Surgical (ISRG): Strong Fundamentals Priced In - Canaccord
-
LSI Industries (LYTS) PT Raised to $10 at Canaccord Genuity Following Q2 Earnings Report
-
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
Canaccord Genuity's US Research team cites RYU Apparel positioned within "Retail's Next Growth Areas."
-
ConforMIS Inc (CFMS) Prices 13.33M Shares Common Offering at $1.50/Sh
-
ConforMIS Announces Pricing of Public Offering of Common Stock
-
Aspen Technology (AZPN) PT Raised to $73 at Canaccord Genuity, Says Equity is Too Expensive for a Buy Rating
-
Aerie Pharma (AERI): Few Hurdles Ahead Of Rhopressa Launch - Canaccord
-
Canaccord Genuity Adds Dedicated Cannabis Investment Banking and Advisory Expertise in the U.S.
-
ConforMIS Inc (CFMS) Announces Proposed Common Share Offering
-
ConforMIS Announces Proposed Public Offering of Common Stock
-
Biogen (BIIB) PT Raised to $350 at Canaccord Genuity Ahead of 4Q17 Earnings Announcement on 1/25 BMO; 'Lower Tax Rate in 2018+ Main Driver'
-
Record Attendance at Canaccord Genuity Blockchain Conference
-
Aurora Cannabis and CanniMed Therapeutics Agree to Terms on Friendly Transaction
-
Skyworks Solutions (SWKS) PT Lowered to $115 at Canaccord Genuity on 'Softer 1H/C2018 iPhone Estimates'
-
UPDATE: Apple (AAPL) PT Raised to $200 at Canaccord Genuity on U.S. Smartphone Survey Data; 'Strong iPhone Sales During December Quarter'
-
iAnthus to Present at Canaccord Genuity's Cannabis Investor Day
-
Obalon Therapeutics (OBLN) Terminates Offering of Common Stock After Whistleblower Contacts Auditor KPMG
-
Obalon Announces Termination of Public Offering of Common Stock
-
Obalon Announces Termination of Public Offering of Common Stock
-
Adobe (ADBE ) PT Raised to $220 at Canaccord Genuity
-
Netflix, Inc. (NFLX): Confident In Near And Mid Term Fundamentals - Canaccord
-
Netflix shares hit record high after blockbuster results
-
Histogenics (HSGX) Prices 2.34M Common Shares at $2.35/Sh
-
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
-
Canada's small financial firms get buzz from weed stocks
-
TipRanks Identifies the Top 20 Analysts of 2017
-
Canaccord Tells Clients to 'stick with' Nuance Communications (NUAN), Could Retest Recent Highs
-
Captor Increases Size of Offering and Retains Canacord Genuity as Financial Advisor
-
Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization
-
Canaccord Genuity Resumes Neovasc (NVCN) at Buy
-
Atara Biotherapeutics (ATRA) PT Raised to $70 at Canaccord Genuity, 'see strong outcome for Phase 3 data based on prior studies'
-
Obalon Therapeutics (OBLN) Prices 5.45m Share Common Offering at $5.50/Sh
-
Obalon Therapeutics Prices Public Offering of Common Stock
-
Obalon Therapeutics Prices Public Offering of Common Stock
-
Thoma Bravo Acquires and Merges Motus and Runzheimer to Create Market Leading Vehicle Management Platform
-
Exact Sciences (EXAS) Selloff 'Overblown' Says Canaccord, 'We Would Aggressively Buy'
-
Biogen (BIIB) PT Raised to $350 at Canaccord Genuity on Lower Tax Rate; 'Remain Constructive Around Business Development'
-
Qualcomm (QCOM) PT Raised to $86 at Canaccord Genuity; 'Management Presents Case to Remain Independent, Introduces $1B Cost Reduction Program'
-
PlacementTracker Publishes 2017 PIPE and Private Placement Markets League Tables
-
NeuroMetrix (NURO), GlaxoSmithKline (GSK) Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
-
Canaccord Genuity Downgrades Goldcorp (GG) to Hold
-
NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
-
Canaccord Genuity Upgrades IAMGOLD (IAG) to Buy Following Investor Day
-
Obalon Therapeutics (OBLN) Commences $35M Offering of Common Stock
-
Obalon Therapeutics Announces Proposed Public Offering of Common Stock

